Pancreatic Cancer Diagnostic Tests-Medical Devices Pipeline Assessment 2017

Publisher's Medical Devices sector report, "Pancreatic Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2017" provides an overview of Pancreatic Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Pancreatic Cancer Diagnostic Tests pipeline products.

For more information about this report at

This report is prepared using data sourced from in-house databases, secondary and primary research by Publisher's team of industry experts.


-Extensive coverage of the Pancreatic Cancer Diagnostic Tests under development
-The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
-The report reviews the major players involved in the development of Pancreatic Cancer Diagnostic Tests and list all their pipeline projects
-The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
-The report provides key clinical trial data of ongoing trials specific to pipeline products
-Recent developments in the segment / industry

Request a sample copy at

Reasons to buy

The report enables you to-
-Formulate significant competitor information, analysis, and insights to improve R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand important and diverse types of Pancreatic Cancer Diagnostic Tests under development
-Develop market-entry and market expansion strategies
-Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
-In-depth analysis of the product's current stage of development, territory and estimated launch date

Companies Mentioned

A&G Pharmaceutical Inc
Abcodia Ltd
Advanced Marker Discovery SL
Andraka Technologies, LLC
Applied Proteomics Inc
Avant Diagnostics, Inc.
BioMarker Strategies LLC
Bioprognos SL
Biouniversa srl
Cancer Research Technology Ltd
Clovis Oncology Inc
CompanDX Ltd.
Courtagen Life Sciences Inc
CS-Keys, Inc.
Di.V.A.L Toscana srl
Exact Sciences Corp
Fred Hutchinson Cancer Research Center
German Cancer Research Center
Health Discovery Corp
Hebrew University of Jerusalem
ImmunoCellular Therapeutics Ltd
Immunomedics Inc
Immunovia AB
Imperial College London
IV Diagnostics, Inc.
John Hopkins University
Leitat Technological Center
Luminor Medical Technologies Inc
Matrix-Bio, Inc.
Mayo Clinic US
MDNA Life Sciences Inc
Merrimack Pharmaceuticals Inc
Metanomics Health GmbH
Milagen Inc
Myriad Genetics Inc
Nanocytomics LLC
NanoScale Corporation
NatiMab Therapeutics Srl
National Cheng-Kung University Hospital
Oncomatryx Biopharma SL
Onconome, Inc.
OPKO Health Inc
Oxford Gene Technology Ltd
PeriRx LLC
Precision Biologics Inc
Proplex Technologies Llc
Protagen AG
Proteome Sciences Plc
Queen Mary University of London
Rutgers The State University of New Jersey
Sienna Cancer Diagnostics Ltd
SomaLogic Inc

Inquire for Report at

Contact Us:
Call: +1-646-491-9876
Email: [email protected]

Posted by on Tuesday September 19 2017, 4:30 PM EDT. All trademarks acknowledged. Filed under Featured Press Release. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Log in